Welcome to the News & More section. Here you will find general information in the form of press releases, news and the latest graphical material.
Berlin-Chemie has been developing, manufacturing and distributing pharmaceutical products for over 130 years and has been a wholly owned subsidiary of the Menarini Group, the leading Italian pharmaceutical company, since 1992.
For patients, we provide the latest patient information leaflets and training materials as well as the technical information for Berlin-Chemie products available in Germany via our Medical Hub.
Responsibility is a top priority at Berlin-Chemie. We not only make an important contribution to healthcare, but also put our values into practice through various social initiatives.
Discover More about Global Responsibility
From school kits to free meals and medicines, to caring for the environment around the world. In Menarini, being responsible means translating our values into concrete actions that are good for others and good for the planet
Berlin-Chemie – a strong partner. Our many years of experience and the success of joint projects make us the partner of choice.
Discover More about Global Partnering
Menarini has in-depth know-how in many important therapeutic areas, thanks to many years of excellent market introduction, marketing and sales capabilities as well as expertise in regulatory aspects and market access. Collaboration is the key to great success, and at Menarini, partnership is part of the DNA.
Our holistic and professional health management offers doctors individual counselling, training or workshops, events and lectures on many topics, depending on their needs.
Our Medical Hub acts as a central point of contact for doctors and healthcare professionals. Here you will find all the information about our medications, additional service and training opportunities.
Menarini Blog
Follow Us
We employ professionals with a wide variety of career backgrounds and are employers who care about their staff. Together, we stand for innovation and reliability.
Our Job Portal
Find out about our current vacancies at Berlin-Chemie directly on our career portal.
2011 - 02 - 23
Tomorrow in Florence, the convention organised to celebrate the Menarini Group’s 125th anniversary
Florence, 23 February 2011
PRESS RELEASE
Tomorrow in Florence, the convention organised
to celebrate the Menarini Group’s 125th anniversary
Florence, 23 February 2011 – To be held in Florence tomorrow, the event ‘Menarini’s research: today’s value, tomorrow’s challenges’, to celebrate the 125 years of the Menarini Group’s history and pharmaceutical research.
The meeting will be held in the Salone dei Cinquecento in Palazzo Vecchio, with the Mayor of Florence, Matteo Renzi giving the welcoming speech.
A large turnout is expected, with institutional representatives, journalists, and leading figures from the scientific community.
Backed by the presence of prominent names in the world of medicine and research, the Menarini Group will retrace its 125 years’ of history with an eye to the future. It will address the developments in the action mechanism of nitric oxide, focusing on the Mimosa Study regarding the prevention of possible relapses of ovarian cancer, and illustrating the new frontiers of Menarini’s research.
Distinguished guests will include Louis J. Ignarro, Nobel Prize for Medicine and Physiology, Jonathan S. Berek of the Stanford University, Sergio Dompè, President of Farmindustria, and Domenico Regoli of the University of Ferrara. Speakers from the Menarini Group will include Carlo Alberto Maggi, Director of Research and Development, Angela Capriati, Director of Clinical Research, and Andrew Slade, President of Menarini Biotech, while Enrico Garaci, President of the Higher Health Institute, and Gianfranco Gensini, Dean of the School of Medicine of the University of Florence will be moderating.
The event can also be visited on the Menarini Group’s company website: www.menarini.com
A preliminary meeting will be held with journalists at 11.30 in the Salone de’ Dugento in Palazzo Vecchio.
For more information please contact Press Office